Form 4: Castle Biosciences Director Converts Vested RSUs and Receives New Equity Grant

Miles Harrison, a Director at Castle Biosciences Inc., reported the conversion of 8,673 vested Restricted Stock Units into common stock and the subsequent grant of 13,667 new Restricted Stock Units.

Summary

• Miles Harrison, a Director of Castle Biosciences Inc. (CSTL), reported two equity transactions in a recent SEC Form 4 filing.
• On May 21, 2025, Mr. Harrison converted 8,673 Restricted Stock Units (RSUs) into an equal number of common shares of Castle Biosciences. This transaction is coded 'M' for exercise or conversion of a derivative security.
• Following this conversion, Mr. Harrison's direct beneficial ownership of common stock increased to 21,964 shares.
• On May 22, 2025, Mr. Harrison was granted an additional 13,667 Restricted Stock Units. These new RSUs were acquired at a price of $0.
• Each RSU represents the right to receive one share of the Issuer's Common Stock.
• The 8,673 RSUs converted on May 21, 2025, were part of a grant that vested on the earlier of the one-year anniversary of May 23, 2025, or the day immediately preceding the next Annual Meeting of Stockholders.
• The newly granted 13,667 RSUs are scheduled to vest in full on the earlier of the one-year anniversary of May 22, 2026, or the day immediately preceding the next Annual Meeting of Stockholders following the grant date.

Sentiment

Score: 6

Explanation: The filing reports standard equity compensation activities for a director, including the conversion of vested units and a new grant. This is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests, but does not indicate significant new operational or financial performance.

Positives

• The grant of 13,667 new Restricted Stock Units to a director aligns management's long-term incentives with shareholder value creation.
• The conversion of 8,673 RSUs into common stock demonstrates the realization of previously earned equity compensation by the director, increasing their direct ownership stake in the company.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The grant of Restricted Stock Units to a director constitutes a related party transaction, as it involves equity compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The transactions increase the director's direct ownership and align their long-term interests with shareholder value, potentially fostering better governance and performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The newly granted 13,667 Restricted Stock Units are expected to vest on the earlier of May 22, 2026, or the day immediately preceding the next Annual Meeting of Stockholders.

Key Dates

Recommendation

Keywords

Castle Biosciences, CSTL, Form 4, SEC filing, insider transaction, Restricted Stock Units, RSU, equity compensation, director stock ownership, stock conversion, equity grant